# ARTV (Artiva Biotherapeutics, Inc.) - SEC EDGAR Financial Statements

> Artiva Biotherapeutics, Inc. reported $0 in revenue and a net loss of $98.11M for the fiscal year ended December 31, 2025 (down 100.0% year over year).

- Canonical: https://convexityos.com/fundamentals/ARTV
- Markdown: https://convexityos.com/fundamentals/ARTV.md
- SEC CIK: 0001817241
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:44 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001817241&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $0 | -100.0% YoY |
| Operating Income | FY 2025 | -$105.2M | Operating profit |
| Net Income | FY 2025 | -$98.11M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.92 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$86.60M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $319.1M | Total debt: $9.17M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Revenue** | $0 | $251K | $33.49M |
| Research & Development | $69.54M | $50.33M | $50.25M |
| Total Operating Expenses | $89.81M | $67.53M | $64.16M |
| **Operating Income** | -$89.81M | -$67.28M | -$30.67M |
| **EBITDA** | -$87.21M | -$64.85M | -$28.41M |
| Income Before Tax | -- | -$65.37M | -$28.65M |
| Income Tax Expense | $0 | $0 | $72K |
| **Net Income** | -$83.86M | -$65.37M | -$28.72M |
| Basic EPS | -$3.43 | -$5.81 | -$35.78 |
| **Diluted EPS** | -$3.43 | -$5.81 | -$35.78 |
| Basic Shares Outstanding | 24.4M | 11.3M | 802.7K |
| Diluted Shares Outstanding | 24.4M | 11.3M | 802.7K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | -- | -- | -- | -- | $0 |
| Research & Development | $25.99M | $21.93M | $19.31M | $16.99M | $17.63M | $17.86M | $17.05M | $13.32M |
| Total Operating Expenses | $31.95M | $26.89M | $24.43M | $21.93M | $22.90M | $22.81M | $22.17M | $18.27M |
| **Operating Income** | -$31.95M | -$26.89M | -$24.43M | -$21.93M | -$22.90M | -$22.81M | -$22.17M | -$18.27M |
| **EBITDA** | -$31.20M | -$26.20M | -$23.76M | -$21.27M | -$22.23M | -$22.17M | -$21.54M | -$17.65M |
| **Net Income** | -$28.82M | -$25.00M | -$23.52M | -$20.77M | -$21.53M | -$21.25M | -$20.31M | -$16.09M |
| Basic EPS | -$0.56 | -$0.63 | -$0.95 | -- | -$0.88 | -$0.87 | -$0.83 | -- |
| **Diluted EPS** | -$0.56 | -$0.63 | -$0.95 | -- | -$0.88 | -$0.87 | -$0.83 | -- |
| Basic Shares Outstanding | 51.2M | 39.4M | 24.7M | -- | 24.5M | 24.4M | 24.3M | -- |
| Diluted Shares Outstanding | 51.2M | 39.4M | 24.7M | -- | 24.5M | 24.4M | 24.3M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $26.70M | $40.23M | $53.50M |
| Short-Term Investments | $81.31M | $145.2M | $23.47M |
| **Cash & Short-Term Investments** | $108.0M | $185.4M | $76.97M |
| Accounts Receivable, Net | -- | $0 | $1.03M |
| **Total Current Assets** | $112.7M | $188.6M | $79.82M |
| Property, Plant & Equipment, Net | $6.62M | $6.37M | $8.10M |
| Other Non-Current Assets | $458K | $267K | $392K |
| **Total Non-Current Assets** | $18.27M | $20.95M | $25.29M |
| **Total Assets** | $130.9M | $209.6M | $105.1M |
| Accounts Payable | $355K | $1.12M | $614K |
| Other Current Liabilities | $73K | -- | -- |
| **Total Current Liabilities** | $13.09M | $12.25M | $12.23M |
| Other Non-Current Liabilities | -- | $73K | $73K |
| **Total Non-Current Liabilities** | $7.88M | $10.69M | $38.49M |
| **Total Liabilities** | $20.97M | $22.94M | $50.72M |
| **Total Debt (incl. Leases)** | $10.94M | $14.35M | $16.91M |
| Common Stock | $3.0K | $3.0K | -- |
| Retained Earnings | -$330.5M | -$246.7M | -$181.3M |
| Accumulated Other Comp. Income | $103K | -$129K | $308K |
| **Total Stockholders' Equity** | $110.0M | $186.6M | -$162.0M |
| Total Equity | $110.0M | $186.6M | -$162.0M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $61.23M | $301.5M | $20.95M | $26.70M | $25.51M | $28.47M | $30.40M | $40.23M |
| Short-Term Investments | $257.9M | $47.94M | $65.83M | $81.31M | $97.46M | $113.9M | $135.6M | $145.2M |
| **Cash & Short-Term Investments** | $319.1M | $349.4M | $86.80M | $108.0M | $123.0M | $142.4M | $166.0M | $185.4M |
| Accounts Receivable, Net | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Total Current Assets** | $326.2M | $352.3M | $88.74M | $112.7M | $129.5M | $149.1M | $170.0M | $188.6M |
| Property, Plant & Equipment, Net | $6.17M | $5.67M | $6.22M | $6.62M | $6.98M | $6.89M | $7.06M | $6.37M |
| Other Non-Current Assets | $1.31M | $809K | $458K | $458K | $418K | $38K | $13K | $267K |
| **Total Non-Current Assets** | $16.73M | $16.36M | $17.21M | $18.27M | $19.34M | $20.32M | $21.26M | $20.95M |
| **Total Assets** | $343.0M | $368.6M | $106.0M | $130.9M | $148.9M | $169.4M | $191.3M | $209.6M |
| Accounts Payable | $2.04M | $1.39M | $2.29M | $355K | $848K | $1.22M | $2.04M | $1.12M |
| Other Current Liabilities | -- | -- | -- | $73K | $73K | $73K | $73K | -- |
| **Total Current Liabilities** | $16.41M | $14.58M | $10.88M | $13.09M | $11.12M | $10.77M | $12.20M | $12.25M |
| Other Non-Current Liabilities | -- | -- | -- | -- | -- | -- | -- | $73K |
| **Total Non-Current Liabilities** | $5.85M | $6.55M | $7.23M | $7.88M | $8.52M | $9.58M | $10.28M | $10.69M |
| **Total Liabilities** | $22.26M | $21.13M | $18.11M | $20.97M | $19.64M | $20.35M | $22.48M | $22.94M |
| **Total Debt (incl. Leases)** | $9.17M | $9.85M | $10.26M | $10.94M | $11.69M | $13.22M | $14.00M | $14.35M |
| Common Stock | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K |
| Retained Earnings | -$407.9M | -$379.1M | -$354.1M | -$330.5M | -$309.8M | -$288.2M | -$267.0M | -$246.7M |
| Accumulated Other Comp. Income | -$1.25M | -$21K | -$18K | $103K | $87K | $2.0K | -- | -$129K |
| **Total Stockholders' Equity** | $320.7M | $347.5M | $87.85M | $110.0M | $129.2M | $149.0M | $168.8M | $186.6M |
| Total Equity | $320.7M | $347.5M | $87.85M | $110.0M | $129.2M | $149.0M | $168.8M | $186.6M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$83.86M | -$65.37M | -$28.72M |
| Depreciation & Amortization | $2.60M | $2.43M | $2.27M |
| Stock-Based Compensation | $6.82M | $6.98M | $7.05M |
| Change in Receivables | $0 | $1.03M | -$510K |
| Change in Payables | -$760K | $519K | -$408K |
| **Operating Cash Flow** | -$76.75M | -$55.03M | -$47.43M |
| Capital Expenditure | -$2.59M | -$642K | -$3.26M |
| **Free Cash Flow** | -$79.34M | -$55.67M | -$50.69M |
| Purchases of Investments | -$44.88M | -$176.2M | -- |
| Sales & Maturities of Investments | $110.9M | $56.35M | -- |
| **Investing Cash Flow** | $63.41M | -$120.5M | -$25.98M |
| Common Stock Issued | $0 | $166.5M | -- |
| **Financing Cash Flow** | $9.0K | $162.2M | $24.39M |
| **Net Change in Cash** | -$13.33M | -$13.27M | -$49.01M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$28.82M | -$25.00M | -$23.52M | -$20.77M | -$21.53M | -$21.25M | -$20.31M | -$16.09M |
| Depreciation & Amortization | $754K | $692K | $666K | $666K | $662K | $641K | $628K | $614K |
| Stock-Based Compensation | $2.80M | $1.86M | $1.59M | $1.59M | $1.63M | $1.55M | $2.05M | $2.18M |
| Change in Receivables | -- | -- | -- | -- | -- | -- | -- | $569K |
| Change in Payables | $506K | -$780K | $1.81M | -$150K | -$442K | -$209K | $41K | -$82K |
| **Operating Cash Flow** | -$28.45M | -$20.36M | -$20.95M | -$14.73M | -$19.20M | -$22.98M | -$19.84M | -$14.65M |
| Capital Expenditure | -$1.04M | -$415K | -$242K | -$421K | -$600K | -$1.05M | -$511K | -$64K |
| **Free Cash Flow** | -$29.49M | -$20.77M | -$21.19M | -$15.15M | -$19.80M | -$24.04M | -$20.35M | -$14.71M |
| Purchases of Investments | -$235.5M | $0 | -$6.44M | -$7.54M | -$12.74M | -$6.07M | -$18.52M | -$14.85M |
| Sales & Maturities of Investments | $24.81M | $18.00M | $22.00M | $24.00M | $29.62M | $28.25M | $29.00M | $13.95M |
| **Investing Cash Flow** | -$211.7M | $17.59M | $15.32M | $16.04M | $16.28M | $21.12M | $9.97M | -$966K |
| **Financing Cash Flow** | -$26K | $283.3M | -$112K | -$121K | -$37K | -$72K | $239K | -- |
| **Net Change in Cash** | -$240.2M | $280.5M | -$5.75M | $1.19M | -$2.96M | -$1.93M | -$9.63M | -$15.65M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Operating Margin** | -- | -26805.6% | -91.6% |
| **Net Profit Margin** | -- | -26045.0% | -85.8% |
| Return on Equity (ROE) | -76.3% | -35.0% | -- |
| Return on Assets (ROA) | -64.0% | -31.2% | -27.3% |
| Current Ratio | 8.61x | 15.39x | 6.53x |
| Quick Ratio | 8.25x | 15.13x | 6.38x |
| Debt to Equity | 0.10x | 0.08x | -- |
| **Revenue Growth (YoY)** | -100.0% | -99.3% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -- | -- | -- | -- | -- | -26806.4% |
| **Net Profit Margin** | -- | -- | -- | -- | -- | -- | -- | -26045.0% |
| Return on Equity (ROE) | -30.6% | -26.1% | -99.1% | -76.3% | -61.3% | -50.4% | -42.5% | -35.0% |
| Return on Assets (ROA) | -28.6% | -24.6% | -82.2% | -64.0% | -53.2% | -44.4% | -37.5% | -31.2% |
| Current Ratio | 19.88x | 24.16x | 8.16x | 8.61x | 11.65x | 13.84x | 13.93x | 15.39x |
| Quick Ratio | 19.45x | 23.96x | 7.98x | 8.25x | 11.06x | 13.22x | 13.60x | 15.13x |
| Debt to Equity | 0.03x | 0.03x | 0.12x | 0.10x | 0.09x | 0.09x | 0.08x | 0.08x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
